中国药师
中國藥師
중국약사
China Pharmacist
2015年
11期
1914-1915,1921
,共3页
左卡尼汀%维持性血液透析%血红蛋白%血清白蛋白%血脂%血清炎症因子
左卡尼汀%維持性血液透析%血紅蛋白%血清白蛋白%血脂%血清炎癥因子
좌잡니정%유지성혈액투석%혈홍단백%혈청백단백%혈지%혈청염증인자
Levocarnitine%Maintenance hemodialysis%Hemoglobin%Albumin%Blood lipid%Serum inflammatory factors
目的：：探讨左卡尼汀辅助治疗对维持性血液透析( MHD)患者血清营养指标及炎症因子水平的影响。方法：62例MHD患者随机分为观察组与对照组各31例。观察组患者每次透析结束后给予左卡尼汀注射液1 g iv,对照组患者给予等容量0.9%氯化钠注射液 iv,均治疗3个月。比较两组患者治疗前后血红蛋白( Hb)、白蛋白( Alb)、总胆固醇( TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)等营养指标及C反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)及肿瘤坏死因子-α(TNF-α)等炎症因子水平变化。结果：治疗后,观察组血清Hb、Alb水平较治疗前明显提高(P<0.05),而血清TC、TG、HDL-C及LDL-C水平无明显变化(P>0.05)；对照组各项指标治疗前后均无明显变化(P>0.05)；观察组患者治疗后血清Hb、Alb水平明显高于对照组(P<0.05)。观察组患者血清CRP、IL-6、IL-8及TNF-α水平均较治疗前明显降低(P<0.05),而对照组各项指标治疗前后无明显变化(P>0.05)；观察组治疗后各项指标均明显低于对照组(P<0.05)。结论：左卡尼汀辅助治疗MHD患者能明显改善患者营养状态及微炎症状态,且对机体血脂代谢不会造成明显影响,对降低并发症的发生,提高患者预后生活质量具有非常重要的价值,值得临床进一步推广应用。
目的：：探討左卡尼汀輔助治療對維持性血液透析( MHD)患者血清營養指標及炎癥因子水平的影響。方法：62例MHD患者隨機分為觀察組與對照組各31例。觀察組患者每次透析結束後給予左卡尼汀註射液1 g iv,對照組患者給予等容量0.9%氯化鈉註射液 iv,均治療3箇月。比較兩組患者治療前後血紅蛋白( Hb)、白蛋白( Alb)、總膽固醇( TC)、三酰甘油(TG)、低密度脂蛋白膽固醇(LDL-C)、高密度脂蛋白膽固醇(HDL-C)等營養指標及C反應蛋白(CRP)、白細胞介素-6(IL-6)、白細胞介素-8(IL-8)及腫瘤壞死因子-α(TNF-α)等炎癥因子水平變化。結果：治療後,觀察組血清Hb、Alb水平較治療前明顯提高(P<0.05),而血清TC、TG、HDL-C及LDL-C水平無明顯變化(P>0.05)；對照組各項指標治療前後均無明顯變化(P>0.05)；觀察組患者治療後血清Hb、Alb水平明顯高于對照組(P<0.05)。觀察組患者血清CRP、IL-6、IL-8及TNF-α水平均較治療前明顯降低(P<0.05),而對照組各項指標治療前後無明顯變化(P>0.05)；觀察組治療後各項指標均明顯低于對照組(P<0.05)。結論：左卡尼汀輔助治療MHD患者能明顯改善患者營養狀態及微炎癥狀態,且對機體血脂代謝不會造成明顯影響,對降低併髮癥的髮生,提高患者預後生活質量具有非常重要的價值,值得臨床進一步推廣應用。
목적：：탐토좌잡니정보조치료대유지성혈액투석( MHD)환자혈청영양지표급염증인자수평적영향。방법：62례MHD환자수궤분위관찰조여대조조각31례。관찰조환자매차투석결속후급여좌잡니정주사액1 g iv,대조조환자급여등용량0.9%록화납주사액 iv,균치료3개월。비교량조환자치료전후혈홍단백( Hb)、백단백( Alb)、총담고순( TC)、삼선감유(TG)、저밀도지단백담고순(LDL-C)、고밀도지단백담고순(HDL-C)등영양지표급C반응단백(CRP)、백세포개소-6(IL-6)、백세포개소-8(IL-8)급종류배사인자-α(TNF-α)등염증인자수평변화。결과：치료후,관찰조혈청Hb、Alb수평교치료전명현제고(P<0.05),이혈청TC、TG、HDL-C급LDL-C수평무명현변화(P>0.05)；대조조각항지표치료전후균무명현변화(P>0.05)；관찰조환자치료후혈청Hb、Alb수평명현고우대조조(P<0.05)。관찰조환자혈청CRP、IL-6、IL-8급TNF-α수평균교치료전명현강저(P<0.05),이대조조각항지표치료전후무명현변화(P>0.05)；관찰조치료후각항지표균명현저우대조조(P<0.05)。결론：좌잡니정보조치료MHD환자능명현개선환자영양상태급미염증상태,차대궤체혈지대사불회조성명현영향,대강저병발증적발생,제고환자예후생활질량구유비상중요적개치,치득림상진일보추엄응용。
Objective:To explore the effects of levocarnitine adjunctive therapy on serum nutritional index and inflammatory factor level in maintenance hemodialysis patients. Methods:Totally 62 patients with hemodialysis were randomly divided into the observation group and the control group with 31 cases in each. The observation group was treated with 1g levocarnitine injection with intravenous in-jection after the dialysis, and the control group was treated with 0. 9% physiological saline injection with the same volume after the di-alysis. After 3-month treatment, the nutritional indices including Hb, Alb, TC, TG, LDL-C and HDL-C and the change in inflamma-tory factors including C-reactive protein (CRP), IL-6, IL-8 and TNF-α of the patients in the two groups were studied and compared. Results:After the treatment, the level of Hb and Alb was improved in the observation group (P<0. 05), while the level of TC, TG, HDL-C and LDL-C had no significant change (P>0. 05). All of the indices showed no significant change in the control group (P>0. 05). After the treatment, the level of Hb and Alb in the observation group was higher than that in the control group (P<0. 05). After the treatment, the level of CRP, IL-6, IL-8 and TNF-α was reduced in the observation group (P<0.05), while the control group had no significant changes in the indices (P>0. 05). All of the indices in the observation group was better than those in the control group (P<0. 05). Conclusion:Levocarnitine used in the treatment of patients with hemodialysis can effectively improve the nutritional status and inflammatory factors level without obvious effects on lipid metabolism, which is very important for the reduction of complication and the improvement of life quality, and worthy of clinical promotion.
